Diagnosis and treatment of leptomeningeal metastases from solid tumors: Experience with 90 patients
- 15 February 1982
- Vol. 49 (4) , 759-772
- https://doi.org/10.1002/1097-0142(19820215)49:4<759::aid-cncr2820490427>3.0.co;2-7
Abstract
The clinical findings and response to treatment of leptomeningeal metastases from solid tumors are analyzed in 90 patients treated at Memorial Sloan-Kettering Cancer Center during the period from January 1975 to February 1980. Patients included those who had either typical clinical findings of leptomeningeal tumor or conclusive laboratory evidence supporting the diagnosis. Carcinoma of the breast (46 patients), lung (23 patients) and melanoma (11 patients) were the common primary tumors. Symptoms of leptomeningeal metastasis occurred as the presenting sign in five patients and as late as ten years after the primary tumor was diagnosed in four other patients. Most patients had active systemic disease outside the nervous system. Signs and symptoms could be classified as involving either the brain, cranial nerves, or spinal nerves. Most patients had either symptoms or signs in more than one area at the time the diagnosis was established. The initial spinal fluid examination was abnormal in all but three patients, but only 49 had cytologic evidence of leptomeningeal metastases. Repeated spinal fluid assay yielded a positive cytology in 82 patients. Measurement of biochemical markers, including β-glucuronidase, carcinoembryonic antigen and lactic dehydrogenase, assisted in the diagnosis. Approximately half of the patients treated by intraventricular methotrexate experienced improvement or stabilization of neurological symptoms for more than a month; median survival was 5.8 months after diagnosis, with a range of 1–29 months. In 18 patients disease was limited to the nervous system, and median survival was eight months, with four patients surviving one year and two patients for two years. Side effects of therapy were, for the most part, minor. We conclude that vigorous treatment of leptomeningeal metastases with intrathecal chemotherapeutic agents improves symptomatology in some patients, and at times prolongs survival.This publication has 39 references indexed in Scilit:
- Lactic dehydrogenase isoenzymes in the cerebrospinal fluid of patients with systemic cancerCancer, 1981
- Radation therapy for brain metastasesAnnals of Neurology, 1980
- Malignant cells in cerebrospinal fluid (CSF)Neurology, 1979
- Intraventricular versus intralumbar methotrexate for central‐nervous‐system leukemia: Prolonged remission with the ommaya reservoirMedical and Pediatric Oncology, 1979
- Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: leukemia revisitedBlood, 1976
- Ommaya Device in Carcinomatous and Leukemic Meningitis: Surgical Experience in 45 CasesSurgical Clinics of North America, 1974
- Treatment of central nervous system leukemia with intrathecal cytosine arabinosideCancer, 1973
- Lymphomatous leptomeningitisThe American Journal of Medicine, 1971
- The increasing incidence of central nervous system leukemia in children.(Children's cancer study group a)Cancer, 1970
- Diffuse Leptomeningeal CarcinomatosisNeurology, 1955